<unk>  is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the EU and other regions. The most common side effects for<unk>  (Arzerra) include infusion reactions and neutropenia. The most common side effects for<unk>  (Kesimpta) include upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions. It is sold by Novartis under license from Genmab.
Ofatumumab
Daratumumab
Alirocumab
Lanadelumab
Acalabrutinib
Tralokinumab
Sacituzumab govitecan
Bezlotoxumab